tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2014-1-14-18tumors-2Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL REPORTSРАК МОЛОЧНОЙ ЖЕЛЕЗЫ И БЕРЕМЕННОСТЬ: ОСОБЕННОСТИ ДИАГНОСТИКИ И ЛЕЧЕНИЯBreast cancer and pregnancy: diagnosis and treatmentИвановаО. А.IvanovaO. A.olalivanova@yandex.ruЖильцоваЕ. К.Zhil'tsovaE. K.ziltsova@yandex.ruИвановВ. Г.IvanovV. G.doctorivanov@msn.comПоповаР. Т.PopovaR. T.olalivanova@yandex.ruЕрмоченковаА. М.ErmochenkovaA. M.selivanovanastia@mail.ruФГБУ НИИ онкологии им Н. Н. Петрова МЗРФRussian Federation201419052015011418Copyright © Иванова О.А., Жильцова Е.К., Иванов В.Г., Попова Р.Т., Ермоченкова А.М., 20152015Иванова О.А., Жильцова Е.К., Иванов В.Г., Попова Р.Т., Ермоченкова А.М.Ivanova O.A., Zhil'tsova E.K., Ivanov V.G., Popova R.T., Ermochenkova A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/2

Динамика исследований рака молочной железы в последние годы показала, что он является наиболее частой формой опухоли у женщин во время беременности. По данным международных статистических институтов, на эту форму опухоли у женщин моложе 45 лет приходится до 8% всех случаев. Частота выявляемости РМЖ во время беременности колеблется от 1 на 3000 беременных женщин, до 1 на 10000 случаев беременности [1, 2]. Причина того, что ранее достаточно редкое сочетание РМЖ и беременности в настоящее время уже не является редкостью, заключается в более позднем возрасте деторождения, а также в том, что когорта больных расширяется за счет включения в нее и тех женщин, РМЖ у которых обнаружен в течение одного года после родов

Breast cancer researches in recent years have shown that it is the most common form of cancer in women during pregnancy. According to the data from international statistical institutes, this form of cancer in women younger than 45 years account for 8% of all cases. The frequency of detection of breast cancer during pregnancy ranges from 1 in 10,000 pregnant women to 1 in 3,000 pregnancies.  The reason that a rare combination of breast cancer and pregnancy is no longer a rarity now, is the older age of childbearing, and that the cohort of patients expands to include those women with breast cancer who were diagnosed during one year after childbirth.

рак молочной железыРМЖ при беременностиособенности лечения при РАВСbreast cancerpregnancytreatment in patients with РАВСReferencesMir O., Berveiller P., Ropert S. et al. Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol, 2008; 19: 607–613.Mir O., Berveiller P., Ropert S. et al. Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol, 2008; 19: 607–613.Kahlert S., Bauerfeind I., Strauss A. and UntchM.: Breast cancer treatment during pregnancy — experiences in the department of OB/GYN Grosshadern-Munich and review of international data. Zentralbl Gynakol, 2004; 126 (3): 159–166.Kahlert S., Bauerfeind I., Strauss A. and UntchM.: Breast cancer treatment during pregnancy — experiences in the department of OB/GYN Grosshadern-Munich and review of international data. Zentralbl Gynakol, 2004; 126 (3): 159–166.Andersson T. M., Johansson A. L., Hsieh C. C. et al. Increasing incidence of pregnancy-associated breast cancer in Sweden. Obstet Gynecol, 2009; 114: 568–572. DOI: 10.1097/AOG. 0b013e3181b19154.Andersson T. M., Johansson A. L., Hsieh C. C. et al. Increasing incidence of pregnancy-associated breast cancer in Sweden. Obstet Gynecol, 2009; 114: 568–572. DOI: 10.1097/AOG. 0b013e3181b19154.Altekruse S. F., Kosary C. L., Krapcho M. et al. SEER Cancer Statistics Review 1975–2007. Bethesda, MD: National Cancer Institute, based on November 2009 SEER data submission, posted to the SEER web site, 2010. ht tp://seer.cancer.gov/csr/1975–2007/, accessed November 5, 2010.Altekruse S. F., Kosary C. L., Krapcho M. et al. SEER Cancer Statistics Review 1975–2007. Bethesda, MD: National Cancer Institute, based on November 2009 SEER data submission, posted to the SEER web site, 2010. ht tp://seer.cancer.gov/csr/1975–2007/, accessed November 5, 2010.Nugent P., O’Connell T. X. Breast cancer and pregnancy. Arch Surg 1985; 120: 1221–1224.Nugent P., O’Connell T. X. Breast cancer and pregnancy. Arch Surg 1985; 120: 1221–1224.Clark R. M., Chua T. Breast cancer and pregnancy: The ultimate challenge. Clin Oncol (R Coll Radiol), 1989; 1: 11–18.Clark R. M., Chua T. Breast cancer and pregnancy: The ultimate challenge. Clin Oncol (R Coll Radiol), 1989; 1: 11–18.Deemarsky L., Neishtadt E. Breast cancer and pregnancy. Breast, 1981; 7: 17.Deemarsky L., Neishtadt E. Breast cancer and pregnancy. Breast, 1981; 7: 17.Schackmuth E. M., Harlow C. L., Norton L. W. Milk fistula: A complication af ter core breast biopsy. AJR Am J Roentgenol, 1993; 161: 961–962.Schackmuth E. M., Harlow C. L., Norton L. W. Milk fistula: A complication af ter core breast biopsy. AJR Am J Roentgenol, 1993; 161: 961–962.DeSantis M., Lucchese A., DeCarolis S. et al. Metastatic breast cancer in pregnancy: First case of chemotherapy with docetaxel. Eur J Cancer Care, 2000; 9: 235–237.DeSantis M., Lucchese A., DeCarolis S. et al. Metastatic breast cancer in pregnancy: First case of chemotherapy with docetaxel. Eur J Cancer Care, 2000; 9: 235–237.Birchard K. R., Brown M. A., Hyslop W. B. et al. MRI of acute abdominal and pelvic pain in pregnant patients. Am J Roentgenol, 2005; 184: 452–458.Birchard K. R., Brown M. A., Hyslop W. B. et al. MRI of acute abdominal and pelvic pain in pregnant patients. Am J Roentgenol, 2005; 184: 452–458.Webb J. A., Thomsen H. S., Morcos S. K. Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol, 2005; 15: 1234–1240.Webb J. A., Thomsen H. S., Morcos S. K. Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol, 2005; 15: 1234–1240.Yang W. T., Dryden M. J., Gwyn K. et al. Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy. Radiology, 2006; 239: 52–60.Yang W. T., Dryden M. J., Gwyn K. et al. Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy. Radiology, 2006; 239: 52–60.Elledge R. M., Ciocca D. R., Langone G. and McGuire W. L. Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer, 1993; 71 (8): 2499–2506.Elledge R. M., Ciocca D. R., Langone G. and McGuire W. L. Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer, 1993; 71 (8): 2499–2506.Rio M. C., Bellocq J. P., Gairard B., Rasmussen U. B., Krust A., Koehl C. et al. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA, 1987; 84 (24): 9243–9247.Rio M. C., Bellocq J. P., Gairard B., Rasmussen U. B., Krust A., Koehl C. et al. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA, 1987; 84 (24): 9243–9247.Le Doussal V., Tubiana-Hulin M., Friedman S., Hacene K., Spyratos F. and Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1,262 invasive ductal breast carcinomas. Cancer, 1989; 64 (9): 1914–1921.Le Doussal V., Tubiana-Hulin M., Friedman S., Hacene K., Spyratos F. and Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1,262 invasive ductal breast carcinomas. Cancer, 1989; 64 (9): 1914–1921.Pujol P., Daures J. P., Thezenas S., Guilleux F., Rouanet P. and Grenier J. Changing estrogen and progesterone receptor pat terns in breast carcinoma during the menstrual cycle and menopause. Cancer, 1998; 83 (4): 698–705.Pujol P., Daures J. P., Thezenas S., Guilleux F., Rouanet P. and Grenier J. Changing estrogen and progesterone receptor pat terns in breast carcinoma during the menstrual cycle and menopause. Cancer, 1998; 83 (4): 698–705.Colleoni M., Rotmensz N., Robertson C., Orlando L., Viale G., Renne G. et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol, 2002; 13 (2): 273–279.Colleoni M., Rotmensz N., Robertson C., Orlando L., Viale G., Renne G. et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol, 2002; 13 (2): 273–279.Russo J., Mailo D., Hu Y. F., Balogh G., Sheriff F. and Russo I. H. Breast differentiation and its implication in cancer prevention. Clin Cancer Res, 2005; 11 (2 Pt 2): 931–936.Russo J., Mailo D., Hu Y. F., Balogh G., Sheriff F. and Russo I. H. Breast differentiation and its implication in cancer prevention. Clin Cancer Res, 2005; 11 (2 Pt 2): 931–936.Russo J., Moral R., Balogh G. A., Mailo D. and Russo I. H. The protective role of pregnancy in breast cancer. Breast Cancer Res, 2005; 7 (3): 131–142.Russo J., Moral R., Balogh G. A., Mailo D. and Russo I. H. The protective role of pregnancy in breast cancer. Breast Cancer Res, 2005; 7 (3): 131–142.Sanchez-Barcelo E.J., Cos S., Mediavilla D., Martinez-Campa C., Gonzalez A., Alonso-Gonzalez C. Melatonin–estrogen interactions in breast cancer. J Pineal Res, 2005; 38 (4): 217–222.Sanchez-Barcelo E.J., Cos S., Mediavilla D., Martinez-Campa C., Gonzalez A., Alonso-Gonzalez C. Melatonin–estrogen interactions in breast cancer. J Pineal Res, 2005; 38 (4): 217–222.Tworoger S. S. and Hankinson S. E. Prolactin and breast cancer risk. Cancer Let t, 2006; 243 (2): 160–169.Tworoger S. S. and Hankinson S. E. Prolactin and breast cancer risk. Cancer Let t, 2006; 243 (2): 160–169.Clevenger C. V. Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Dis, 2003; 18: 75–86.Clevenger C. V. Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Dis, 2003; 18: 75–86.Annane K., Bellocq J. P., Brettes J. P. and Mathelin C. Infiltrative breast cancer during pregnancy and conservative surger y. Fetal Diagn Ther, 2005; 20 (5): 442–444.Annane K., Bellocq J. P., Brettes J. P. and Mathelin C. Infiltrative breast cancer during pregnancy and conservative surger y. Fetal Diagn Ther, 2005; 20 (5): 442–444.Doll D. C., Ringenberg Q. S., Yarbro J. W. Antineoplastic agents and pregnancy. Semin Oncol, 1989;16: 337–346.Doll D. C., Ringenberg Q. S., Yarbro J. W. Antineoplastic agents and pregnancy. Semin Oncol, 1989;16: 337–346.Giacalone P., Laffargue F., Bénos P. Chemotherapy for breast carcinoma during pregnancy A French national survey. Cancer, 1999; 86: 2266–2272.Giacalone P., Laffargue F., Bénos P. Chemotherapy for breast carcinoma during pregnancy A French national survey. Cancer, 1999; 86: 2266–2272.Cardonick E., Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol, 2004; 5: 283–291.Cardonick E., Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol, 2004; 5: 283–291.Hahn K. M., Johnson P. H., Gordon N. et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer, 2006; 107: 1219–1226.28. Cardonick E., Dougherty R., Grana G. et al. Breast cancer during pregnancy: Maternal and fetal outcomes. Cancer J, 2010; 16: 76–82.Hahn K. M., Johnson P. H., Gordon N. et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer, 2006; 107: 1219–1226.28. Cardonick E., Dougherty R., Grana G. et al. Breast cancer during pregnancy: Maternal and fetal outcomes. Cancer J, 2010; 16: 76–82.Cunha G. R., Taguchi O., Namikawa R. et al. Teratogenic effects of clomiphene, tamoxifen, and diethylstilbestrol on the developing human female genital tract. Hum Pathol, 1987; 18: 1132–1143.Cunha G. R., Taguchi O., Namikawa R. et al. Teratogenic effects of clomiphene, tamoxifen, and diethylstilbestrol on the developing human female genital tract. Hum Pathol, 1987; 18: 1132–1143.Isaacs R. J., Hunter W., Clark K. Tamoxifen as systemic treatment of advanced breast cancer during pregnancy-case report and literature review. Gynecol Oncol, 2001; 80: 405–408.Isaacs R. J., Hunter W., Clark K. Tamoxifen as systemic treatment of advanced breast cancer during pregnancy-case report and literature review. Gynecol Oncol, 2001; 80: 405–408.Tewari K., Bonebrake R. G., Asrat T. et al. Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet, 1997; 350: 183.Tewari K., Bonebrake R. G., Asrat T. et al. Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet, 1997; 350: 183.Gaillard B., Leng J. J., Grellet J. et al: Transplacental passage of epirubicin [in French]. J Gynecol Obstet Biol Reprod (Paris), 1995; 24: 63–68.Gaillard B., Leng J. J., Grellet J. et al: Transplacental passage of epirubicin [in French]. J Gynecol Obstet Biol Reprod (Paris), 1995; 24: 63–68.Ring A. E., Smith I. E., Jones A., Shannon C., Galani E., Ellis P. A. Chemotherapy for breast cancer during pregnancy: an 18-year e xperience from five London teaching hospitals. J Clin Oncol, 2005; 23 (18): 4192–4197.Ring A. E., Smith I. E., Jones A., Shannon C., Galani E., Ellis P. A. Chemotherapy for breast cancer during pregnancy: an 18-year e xperience from five London teaching hospitals. J Clin Oncol, 2005; 23 (18): 4192–4197.Antoniou A. C., Shenton A., Maher E. R. et al. Parit y and breast cancer risk among BRC A1 and BRCA2 mutation carriers. Breast Cancer Res, 2006; 8: 72.Antoniou A. C., Shenton A., Maher E. R. et al. Parit y and breast cancer risk among BRC A1 and BRCA2 mutation carriers. Breast Cancer Res, 2006; 8: 72.Cullinane C. A., Lubinski J., Neuhausen S. L. et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer, 2005; 117: 988–991.Cullinane C. A., Lubinski J., Neuhausen S. L. et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer, 2005; 117: 988–991.Kotsopoulos J., Lubinski J., Lynch H. T. et al. Age at first birth and the risk of breast cancer in BRC A1 and BRCA2 mutation carriers. Breast Cancer Res Treat, 2007; 105: 221–228.Kotsopoulos J., Lubinski J., Lynch H. T. et al. Age at first birth and the risk of breast cancer in BRC A1 and BRCA2 mutation carriers. Breast Cancer Res Treat, 2007; 105: 221–228.Hsieh C., Wuu J., Trichopoulos D., Adami H. O., Ekbom A. Gender of offspring and maternal breast cancer risk. Int J Cancer, 1999; 81 (3): 335–338.Hsieh C., Wuu J., Trichopoulos D., Adami H. O., Ekbom A. Gender of offspring and maternal breast cancer risk. Int J Cancer, 1999; 81 (3): 335–338.

The authors declare that there are no conflicts of interest present.